AbbVie Inc (ABBV)vsTandem Diabetes Care Inc (TNDM)
ABBV
AbbVie Inc
$255.48
-1.03%
HEALTHCARE · Cap: $442.36B
TNDM
Tandem Diabetes Care Inc
$21.43
+0.14%
HEALTHCARE · Cap: $1.49B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 6083% more annual revenue ($64.39B vs $1.04B). ABBV leads profitability with a 9.8% profit margin vs -6.1%. ABBV earns a higher WallStSmart Score of 73/100 (B).
ABBV
Strong Buy73
out of 100
Grade: B
TNDM
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-74.9%
Fair Value
$151.49
Current Price
$255.48
$103.99 premium
Intrinsic value data unavailable for TNDM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 40.0%
Earnings expanding 290.4% YoY
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Trading at 11.4x book value
Smaller company, higher risk/reward
Weak financial health signals
ROE of -71.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.41 suggests the stock is reasonably priced for its growth.
Bull Case : TNDM
TNDM has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 70.5x leaves little room for execution misses.
Bear Case : TNDM
The primary concerns for TNDM are Price/Book, Market Cap, Piotroski F-Score. Debt-to-equity of 5.67 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while TNDM is a turnaround play — different risk/reward profiles.
TNDM carries more volatility with a beta of 1.54 — expect wider price swings.
ABBV is growing revenue faster at 10.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (73/100 vs 28/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Tandem Diabetes Care Inc
HEALTHCARE · MEDICAL DEVICES · USA
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?